Los Angeles Capital Management LLC Invests $61,000 in Arbutus Biopharma Corporation $ABUS

Los Angeles Capital Management LLC acquired a new stake in Arbutus Biopharma Corporation (NASDAQ:ABUS) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 19,655 shares of the biopharmaceutical company’s stock, valued at approximately $61,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in ABUS. EntryPoint Capital LLC purchased a new position in shares of Arbutus Biopharma during the 1st quarter worth approximately $65,000. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new position in Arbutus Biopharma during the second quarter worth $112,000. Assenagon Asset Management S.A. purchased a new position in Arbutus Biopharma in the second quarter worth $122,000. XTX Topco Ltd raised its position in Arbutus Biopharma by 37.7% in the first quarter. XTX Topco Ltd now owns 72,412 shares of the biopharmaceutical company’s stock worth $253,000 after acquiring an additional 19,831 shares in the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. lifted its holdings in Arbutus Biopharma by 9.1% in the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 76,031 shares of the biopharmaceutical company’s stock valued at $265,000 after acquiring an additional 6,371 shares during the period. Institutional investors and hedge funds own 43.79% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on ABUS shares. Wall Street Zen cut shares of Arbutus Biopharma from a “buy” rating to a “hold” rating in a research note on Saturday. Chardan Capital restated a “buy” rating and set a $5.00 target price on shares of Arbutus Biopharma in a research report on Friday, November 14th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Arbutus Biopharma in a report on Wednesday, October 8th. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $5.00.

Arbutus Biopharma Trading Down 2.0%

Shares of NASDAQ ABUS opened at $4.45 on Wednesday. The company’s 50-day moving average price is $4.48 and its 200 day moving average price is $3.77. Arbutus Biopharma Corporation has a 52 week low of $2.70 and a 52 week high of $5.10. The stock has a market cap of $855.84 million, a price-to-earnings ratio of -15.34 and a beta of 1.07.

Arbutus Biopharma (NASDAQ:ABUS) last announced its quarterly earnings results on Thursday, November 13th. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.05) by $0.01. Arbutus Biopharma had a negative net margin of 352.24% and a negative return on equity of 59.28%. The company had revenue of $0.53 million for the quarter, compared to the consensus estimate of $1.31 million. As a group, research analysts expect that Arbutus Biopharma Corporation will post -0.39 earnings per share for the current year.

Arbutus Biopharma Company Profile

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression.